The new Irvine facility consists of corporate offices and a 15,000sqft, genomics laboratory.
Bernhard Sixt, president and CEO of Agendia, said: “Our new genomics lab’s capacity will allow us to meet the increasing demand for MammaPrint across the US and give physicians and patients optimal test result turnaround and unmatched service and support.
“This expansion places us in an excellent position to continue making advancements in molecular cancer diagnostics and equip oncologists with powerful tools to use in the fight against breast cancer.”
Agendia claimed that its product MammaPrint is the first and only breast cancer recurrence test cleared by the FDA and is reimbursed by an increasing number of payers, covering some 100 million lives today.
Agendia added that MammaPrint plays a central role in the recently initiated I-SPY 2 trial, which is a breast cancer trial and an initiative of the Biomarkers Consortium, a public-private partnership that includes FDA, the National Institutes of Health, and major pharmaceutical companies, led by the Foundation for the National Institutes of Health.
